Renal abnormalities in psoriatic patients: A review

Nephron

Volumn 82, Issue 1, 1999, Pages 1-6

  Heuvels, J ^b   Maximus, A ^b   Bosmans, J L ^b   Lambert, J ^b   De Broe, Marc E ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYCLOSPORIN; ENDOTHELIN;

AMYLOIDOSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FABRY DISEASE; GOUT; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; KIDNEY BIOPSY; KIDNEY DISEASE; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; NAIL PATELLA SYNDROME; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBEROUS SCLEROSIS; URINARY EXCRETION; VASCULITIS;

HUMANS; KIDNEY; KIDNEY DISEASES; MEDLINE; PSORIASIS;

EID: 0033044281     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045359     Document Type: Review

References (42)

1. Stern RS: Psoriasis. Lancet 1997;350:349-353.
2. Arndt KA, LeBoit PE, Robinson JK, Wintoub BU: Cutaneous Medicine and Surgery: An Integrated Program in Dermatology. Philadelphia, Saunders, 1996.
3. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF: Dermatology in General Medicine, ed 4. New York, McGraw-Hill, 1993.
4. Rook AJ, Wilkinson DS, Ebling FJG: Textbook of Dermatology. Oxford, Blackwell Scientific, 1992.
5. Zachariae H, Heickendorff L, Bjerring P: Plasma endothelin in psoriasis: Possible relations to therapy and toxicity. Acta Derm Venereol 1996;76:442-443.
6. Trevisan G, Stinco G, Giansante C, Fiotti N, Vidimari P, Kokelj F: Psoriasis and endothelins. Acta Derm Venereol 1994;(suppl 186): 139-140.
7. McDonald CJ, Calabresi P: Psoriasis and occlusive disease. Br J Dermatol 1978;99:469-475.
8. Ena P, Madeddu P, Glorioso N, Cerimele D, Rapelli A: High prevalence of cardiovascular diseases and enhanced activity of the reninangiotension system in psoriatic patients. Acta Cardiol 1985;40:199-205.
9. Offidani AM, Ferretti G, Taus M, Simonetti O, Dousset N, Valdiguie P, Curatola G, Bossi G: Lipoprotein peroxidation in adult psoriatic patients. Acta Derm Venereol Suppl (Stockh) 1994;186:38-40.
10. Seckin D, Tokgozoglu L, Akkaya S: Are lipoprotein profile and lipoprotein(a) levels altered in men with psoriasis? J Am Acad Dermatol 1994;31:445-449.
11. Seishima M, Seishima M, Mori S, Noma A: Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994;130: 738-742.
12. Gligora M, Arzensek J, Rems D, Troskot N, Banjanin M: Psoriasis in the third age. Acta Derm Venereol Suppl (Stockh) 1989;146:168-170.
13. Wittenberg GP, Oursler JR, Peters MS: Secondary amyloidosis complicating psoriasis. J Am Acad Dermatol 1995;32:465-468.
14. David M, Abraham D, Weinberger A, Feuerman EJ: Generalised pustular psoriasis, psoriatic arthritis and nephrotic syndrome associated with systemic amyloidosis. Dermatologica 1982;165:168-171.
15. Ahmed Q, Chung-Park M, Mustafa K, Khan MA: Psoriatic spondylarthropathy with secondary amyloidosis. J Rheumatol 1996;23: 1107-1110.
16. Canuel C, Krulik M, Mougeot-Martin M, Laplanche A, Gintzburger S, Genot JY, Audebert AA, Debray J: Psoriatic arthritis with renal amyloidosis. A case-report. Review of the literature. Sem Hôp 1982;58:523-528.
17. Imai H, Kodoma T, Ishina T, Yasuda T, Miura AB, Asakura K, Nishimura S, Nakamoto Y: IgA nephropathy associated with hyper-IgA-globulinemia, psoriasis or pustulosis and ossification. Clin Nephrol 1995;44:64-68.
18. Bruneau C, Villiaumey J, Avouac B, Martigny J, Laurent J, Pichot A, Belghiti D, Lagrue G: Seronegative spondylarthropathies and IgA glomerulonephritis: A report of four cases and a review of the literature. Semin Arthritis Rheum 1986;15:179-184.
19. Madeddu P, Ena P, Glorioso N, Cerimeli D, Rappelli A: High prevalence of microproteinuria, an early index of renal impairment, in patients with psoriasis. Nephron 1988;48:222-225.
20. Utas S, Utas C, Kelestimur F, Bas K, Sahin S, Pasaoglu H, Soyuer U: Urinary albumin excretion in patients with uncomplicated diffuse psoriasis. Acta Derm Venereol 1995;75:88.
21. Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A: Relation between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology 1992;185:93-95.
22. Cecchi R, Giomi A, Ciuti M, Seghieri G: Increased urinary excretion of N-acetyl-β-D-glucosaminidase in patients affected with psoriasis. Acta Derm Venereol 1996;76:492.
23. Madeddu P, Ena P, Parpaglia PP, Patteri G, Bacciu S, Maioli M, Glorioso N: Depressed urinary excretion of epidermal growth factor in psoriasis. Am J Nephrol 1991;11:313-317.
24. Kondo S, Sato N, Aso K: The level of urinary epidermal growth factor is not influenced by the extent of psoriatic lesions. Arch Dermatol Res 1991;283:516-518.
25. Zachariae H, Grunnet E, Sogaard H: Accidental kidney biopsies in psoriasis. Br J Dermatol 1976;94:655-657.
26. Zachariae H, Hansen HE, Sogaard H, Olsen TS: Kidney biopsies in methotrexate-treated psoriatics. Dermatologica 1990;181:273-276.
27. Young EW, Ellis CN, Messana JM, Johnson KJ, Leichtman AB, Mihatsch MJ, Hamilton TA, Groisser DS, Fradin MS, Voorhees JJ: A prospective study of renal structure and function in psoriasis patients treated with cyclosporine. Kidney Int 1994;46:1216-1222.
28. Stühlinger W, Innerebner M, Aberer W: Nephrotoxische Wirkung einer Therapie mit Fumarsäureestern bei Psoriasis. Dtsch Med Wochenschr 1990;115:1712-1715.
29. Mahrle G: Noch einmal: Fumarsäure. Z Hautkr 1991;66:667-668.
30. Schrier RW, Gottschalk CW; Diseases of the Kidney, ed 6. Boston, Little, Brown, 1997, pp 1156-1157.
31. Kremer JM: Methotrexate update. Scand J Rheumatol 1996;25:341-344.
32. Deray G, Khayat D, Cacoub P, Bourbouze R, Musset L, Baumelou A, Jacquillat C, Jacobs C: The effects of diltiazem on methotrexate-induced nephrotoxicity. Eur J Clin Pharmacol 1989;37:337-340.
33. Weinblatt ME: Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985; 12(suppl 12):35-39.
34. Seideman P, Muller-Suur R, Ekman E: Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993;20:1126-1128.
35. Kennedy C, Baker H: Renal function in methotrexate-treated psoriatics (letter). Br J Dermatol 1976;94:702-703.
36. Vercauteren SR, Bosnians JL, Elseviers MM, Verpooten GA, DeBroe ME: A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in autoimmune diseases. Kidney Int 1998;54:536-545.
37. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S: Renal biopsy findings in long-term cyclosporine treatment of psoriasis. Br J Dermatol 1997;136:531-535.
38. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L: Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996;132:623-629.
39. Schrier RW, Gottschalk CW: Diseases of the Kidney, ed 6. Boston, Little, Brown, 1997, p 1128.
40. Charnick SB, Nedelman JR, Chang CT, Hwang DS, Jin J, Moore MA, Wong R, Meligeni J: Description of blood pressure changes in patients beginning cyclosporin A therapy. Ther Drug Monit 1997;19:17-24.
41. Verstrepen WA, Nouwen EJ, Yue XS, De Broe ME: Altered growth factor expression during toxic proximal tubular necrosis and regeneration. Kidney Int 1993;43:1267-1279.
42. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988;ii:530-533.